pharmaphorum January 19, 2022
Jonah Comstock

According to Rock Health’s annual digital health funding report, US-based digital health companies enabling life sciences research and development raised $5.8 billion (£4.3 billion) in 2021, making it the top funded category of the sector.

This is the first time R&D has topped the chart since Rock Health began tracking US digital health funding in 2011, although it nabbed the number two slot in 2018 and 2020.

The San Francisco-based research firm attributed the category’s over-performance to COVID-19’s acting as a forcing function for the digitisation of key pharma processes.

“In 2021, digital health companies catalysing R&D in biopharma and medtech topped the chart with $5.8B in funding, stimulated by the COVID-accelerated adoption of real-world evidence and decentralized trials,” authors...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Digital Health, Investments, Pharma / Biotech, Survey / Study, Technology, Trends
March Fundraising Roundup: 7 Provider Tech Startups That Closed Rounds This Month
Pelago Defies Digital Health Funding Drought, Raises $58M
Digital health venture capital deals stagnate
Finger on the Pulse: The State of Primary Care in the U.S. and Nine Other Countries
Embracing digital transformation with a digital factory

Share This Article